Clinical Trial

A Study of Olverembatinib in SDH-deficient GIST.

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
An international multicenter, open, single-arm pivotal registration phase III study to determine the efficacy and safety of olverembatinib in patients with SDH-deficient gastrointestinal stromal tumor (GIST) who have previously been treated with one-line therapy, and to evaluate the progression-free survival and clinical benefit rate of olverembatinib in patients with SDH-deficient GIST.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-10-11; most recent amendment 2026-07-21.
Status change: Not Yet Recruiting → Recruiting 2024-12-23
Trial Details
NCT Number NCT06640361
Lead Sponsor Ascentage Pharma Group Inc.
Collaborators: HealthQuest Pharma Inc.
Conditions GIST
Enrollment 40 participants
Start Date 2024-11-11
Primary Completion 2027-03-31 (estimated)
Study Completion 2029-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-23